Similar findings have been observed in preclinical models of small-cell lung carcinoma (SCLC) treated with PDL1 antagonists in combination with the CHK1 (mediator of DNA damage response) inhibitor prexasertib [407]. The gene discussed is CHEK1; the disease is small cell lung carcinoma.